The FDA and Centers for Disease Control and Drug Prevention announced Friday that the pause on Johnson & Johnson vaccines has been lifted after further review.
RELATED STORIES: U.S. Calls For Pause On Johnson & Johnson Vaccine After Six Reported Cases Of Rare Blood Clots
Vaccine sites will be able to administer the jab once again after data revealed that it can save lives and prevent COVID-related hospitalizations after a 10-4 vote from the Advisory Committee on Immunization Practices. Despite the risk of rare blood clots, Acting FDA Commissioner Janey Woodstock said in a statement that the benefits outweigh the risks during a press conference earlier this evening.
“Together both agencies have full confidence that this vaccine’s known and potential benefits outweigh its known and potential risks in individuals 18 and older.”
RELATED STORIES: Johnson & Johnson Pauses Covid-19 Vaccine Trial After “Unexplained Illness”
Last week, the vaccine was on pause after six women under the age of 48 developed rare blood clots after recieving the vaccine. One of the women died shortly after receiving the shot. No known cases have been found in men but the CDC has issued an advisory regarding what symptoms to look for after receivng the vaccine.
The vaccine is expected to be distributed and available as of this weekend and the White House said they have 9 million doses ready for the public.
SOURCE: New York Post